Aims: This double-blind, randomized, placebo-controlled trial (ClinicalTrials.gov NCT02453555) evaluated the efficacy and safety of empagliflozin (Empa) 10 or 25 mg as add-on to linagliptin (Lina) 5 mg (fixed-dose combination, Empa/Lina 10/5 or 25/5) in insufficiently controlled Japanese type 2 diabetes patients. who were treatment-naive or were using one oral antidiabetic drug for ≥12 weeks, which was discontinued at enrolment. Patients with HbA1c 7.5%-10.0% after ≥16 weeks of using Lina Results: Change from baseline in HbA1c was greater (P < .0001) with Empa/Lina than with Plc/Lina at Week 24 (primary outcome, −0.93% vs 0.21%; adjusted mean difference, −1.14%) and Week 52 (−1.16% vs 0.06%; adjusted mean difference, −1.22%). More patients with HbA1c < 7.0% and greater decreases in fasting plasma glucose, body weight and systolic blood pressure were seen in the Empa/Lina group than in the Plc/Lina group. Empa/Lina was well tolerated. The adverse events that were more frequent with Empa/Lina were known empagliflozin-associated events (eg, increased urination, increased blood ketones). There were no adjudication-confirmed diabetic ketoacidosis events or lower limb amputations.
| INTRODUCTION
Treatment guidelines for type 2 diabetes mellitus (T2DM) recommend initiating pharmacotherapy with an oral antidiabetic drug (OAD) to reduce hyperglycaemia when diet and exercise are inadequate.
1,2
International guidelines recommend metformin as the first OAD, 1 whereas Japanese guidelines 2 recognize that other OADs may be more appropriate in Japanese patients. [3] [4] [5] Irrespective of the first-line OAD, most patients eventually require an additional OAD with a complementary mechanism to maintain glycaemic control.
1
Dipeptidyl peptidase-4 (DPP-4) inhibitors stimulate glucosedependent insulin secretion via increased levels of active glucagonlike peptide-1 (GLP-1), 6 resulting in lower glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG), with low risk of hypoglycaemia. 6 ,7 DPP-4 inhibitors improve glycaemic control in Asian patients, 8 possibly because Asian patients have reduced insulin secretion capacity, [3] [4] [5] and are the most commonly prescribed OAD in Japan. 9, 10 Linagliptin is a potent and selective DPP-4 inhibitor, with demonstrated efficacy and safety, 7 including in Japanese patients.
11
Unlike other DPP-4 inhibitors, linagliptin is primarily excreted by non-renal elimination routes. 6 Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce plasma glucose by blocking renal glucose reabsorption, thus increasing urinary glucose excretion. 12 The SGLT2 inhibitor empagliflozin is efficacious as monotherapy and as add-on to other OADs, including in Japanese patients. [12] [13] [14] In addition to reducing HbA1c and FPG, empagliflozin reduces body weight, systolic blood pressure (SBP) [12] [13] [14] and the risk of cardiovascular mortality in high-risk patients with T2DM. 15 Randomized trials have demonstrated that single-pill, fixed-dose combinations (FDCs) of empagliflozin and linagliptin reduce HbA1c more than either component alone in treatment-naive patients 16 and as add-on to metformin. 17 Empagliflozin/linagliptin FDCs are also effective in patients who are inadequately controlled with empagliflozin plus metformin 18 or linagliptin plus metformin. 19 However, empagliflozin as add-on to linagliptin has not yet been fully evaluated in Japanese patients in a double-blind, placebo-controlled trial.
The primary objective of this double-blind, randomized, placebo- 
| MATERIALS AND METHODS

| Study details
This was a 52-week, multicentre, phase III, double-blind, doubledummy, randomized, placebo-controlled trial of once-daily empagliflozin/linagliptin FDC compared with linagliptin plus placebo in Japanese patients with T2DM with insufficient glycaemic control after ≥16 weeks of linagliptin 5 mg ( Figure S1 ). The study (ClinicalTrials.gov NCT02453555) was conducted at 40 sites in Japan between May 2015 and March 2017. The study was in compliance with the Japanese Ethical Guideline for Clinical Studies and the Declaration of Helsinki, and was approved by the institutional review board at each site.
All patients provided prior written informed consent.
| Study population
Inclusion criteria included: male and female adults (≥20 years) with a body mass index (BMI) ≤ 40.0 kg/m 2 and a diagnosis of T2DM who had been on a diet and exercise regimen for ≥12 weeks and were either treatment-naive or using a stable dosage of one OAD (sulfonylurea up to half the maximum approved dosage) for ≥12 weeks (≥18 weeks for thiazolidinedione); OADs (except linagliptin) were discontinued at screening. Required HbA1c levels (National Glycohaemo- 
| Study design
To ensure that all patients were pre-treated with linagliptin for 
| Efficacy outcome measures
The primary endpoint was change in HbA1c from baseline (randomiza- 
| Statistical analysis
Based on previous experience, the between-group difference in
HbA1c change from baseline at Week 24 was assumed to be 0.5%, with a standard deviation (SD) of 1.1%. Assuming that 7% of patients discontinued before the up-titration period, 25% would receive up-titrated medication and 3% would be excluded from analysis, as covariates, to obtain odds ratios, 95% CIs and P values. Safety was analysed in randomized patients who received ≥1 dose of study drug and was presented using descriptive statistics. Two-sided P values <.05 were considered significant. Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, North Carolina).
3 | RESULTS
| Patient disposition
Among 433 screened patients, 52 were ineligible, mostly because they 
| Demographic and baseline clinical characteristics
Most (214/275; 78%) patients were men with a mean age of 60 years and~9 years since T2DM diagnosis ( 
| Change in HbA1c
Compared with linagliptin monotherapy, empagliflozin/linagliptin resulted in significantly greater decreases in HbA1c at Weeks 24 (primary endpoint) and 52 ( Figure 1A ). At Week 24, the adjusted mean empagliflozin/linagliptin achieved HbA1c levels <7.0% at Weeks 24 (27.5% vs 5.4%) and 52 (43.4% vs 7.5%; P < .0001 at both timepoints) compared with linagliptin monotherapy (Figure 2 ). [3. 48] mg/dL) compared with linagliptin monotherapy (P < .0001 at both timepoints) ( Figure 3A) . The greater decrease in FPG with empagliflozin/linagliptin occurred by Week 4 and was sustained ( Figure 3B ). P < .0001 at both timepoints) (Table S1 ). 
| Fasting plasma glucose
| Other efficacy outcomes
| Insulin and glucagon
| Safety and tolerability measures
The incidence of AEs was lower in patients receiving empagliflozin/ linagliptin than in patients receiving linagliptin monotherapy (Table 2) . (adrenal neoplasm, lung neoplasm and cerebral haemorrhage), all during the up-titration period, were assessed by the investigators to be drug-related. Of these, the patient with cerebral haemorrhage was receiving Empa/Lina 10/5 during the up-titration period and died atraumatically at home. Although the investigator considered this SAE to be drug-related, the cardiovascular adjudication committee could not confirm the event because of insufficient information (death confirmed by an emergency doctor; no autopsy). There were no other deaths. One patient in the All Plc/Lina 5 group experienced lumbar spinal stenosis during the up-titration period, which was not considered drug-related.
The most common AESIs included infections (primarily nasopharyngitis), urinary tract infection, hypersensitivity, arthralgia and increased urination (Table 2 ). Of these, hypersensitivity and increased urination were more common with the empagliflozin/linagliptin combination than with linagliptin monotherapy. There were no events of urinary tract infection with complications (ie, pyelonephritis, urosepsis). All events relating to "metabolic acidosis, ketoacidosis or DKA"
were, according to the MedDRA Preferred Term, "blood ketone body increased" and were reported by investigators as mild and non-serious. All these events were independently adjudicated, and none were considered DKA. The rate of confirmed hypoglycaemia was low (All Empa/Lina 5, 0%; All Plc/Lina 5, 1.1%). There were no reports of pancreatitis, cardiac failure, acute kidney injury, lower limb amputation, intestinal obstruction or embolic/thrombotic events ( Table 2 ).
There were no confirmed cardiovascular or hepatic events, as judged by the adjudicating committees. Five patients in the All Empa/ 19 This difference may be related to the higher baseline HbA1c and FPG, and the lower BMI and weight, in the current trial, as well as to racial/ethnic differences. 19 Approximately 25% of patients in the previous trial self-identified as Asian and there were no Japanese study sites. 19 Reduction in HbA1c was also (9) 7.5% (7) 7.7% (14) Acute pyelonephritis NA NA 0% (0) 0% (0) Asymptomatic bacteriuria NA NA 6.5% (6) 7.1% ( c Preferred terms included "pollakiuria", "polyuria" and "nocturia".
d Preferred terms were "acetonemia", "acidosis", "anion gap abnormal", "anion gap increased", "blood pH abnormal", "blood pH decreased", "diabetic hyperglycaemic coma", "ketonuria", "ketosis", "Kussmaul respiration", "metabolic acidosis", "blood ketone body", "blood ketone body increased", "urine ketone body present", "blood ketone body present", "urine ketone body", and "diabetic metabolic decompensation"; all observed events were "blood ketone body increased" and were mild and non-serious.
e Preferred terms were "diabetic ketoacidosis", "diabetic ketoacidotic hyperglycaemic coma" and "ketoacidosis".
apparently larger in our trial than that seen with canagliflozin as addon to teneligliptin in Japanese patients (least squares mean difference between groups, −0.88%). 23 Although both trials were conducted in Japan and had similar designs, baseline HbA1c and FPG levels were higher in our trial, possibly contributing to the greater response. The combination of empagliflozin and linagliptin was well tolerated, and observed AEs were as expected for the monocomponents. 7, 27 No cases of confirmed hypoglycaemia were seen, consistent with the mechanisms of action of these drugs. Indeed, several studies have reported that DPP-4/SGLT2 inhibitor combinations do not increase the incidence of hypoglycaemia above the low rate seen with either monocomponent, unless combined with insulin and/or sulfonylureas. [16] [17] [18] 23, 28, 29 Although drug-related AEs were more frequent with empagliflozin/linagliptin than with linagliptin, these were primarily AEs known to be associated with SGLT2 inhibitors (increased blood ketone bodies, cystitis, pollakiuria). 20, 27 No cases of lower limb amputations (which were also not reported in the Japanese canagliflozin-teneligliptin study 23 ), non-traumatic bone fracture, volume depletion (except 1 case of mild orthostatic hypotension) or DKA occurred in patients treated with empagliflozin/linagliptin in this trial.
Notably, Japanese guidelines recommend avoiding multi-drug combination therapy in elderly patients, as these patients are more vulnerable to potential adverse effects. 30 
